213 related articles for article (PubMed ID: 35282455)
1. Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Zhang Y; Liu X; Zhang H; Wang X
Front Endocrinol (Lausanne); 2022; 13():836455. PubMed ID: 35282455
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
Tang X; Zhang H; Wang X; Yang D
Afr Health Sci; 2022 Sep; 22(3):391-398. PubMed ID: 36910362
[TBL] [Abstract][Full Text] [Related]
3. Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
Sun L; Deng C; Gu Y; He Y; Yang L; Shi J
Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101876. PubMed ID: 35321843
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Yang K; Chen J; Zhang T; Yuan X; Ge A; Wang S; Xu H; Zeng L; Ge J
Front Immunol; 2022; 13():949746. PubMed ID: 36159792
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Metformin on Aminotransferase Levels, Metabolic Parameters and Body Mass Index in Nonalcoholic Fatty Liver Disease Patients: A Metaanalysis.
Hu H; Wang J; Li X; Shen L; Shi D; Meng J
Curr Pharm Des; 2021; 27(29):3235-3243. PubMed ID: 33719959
[TBL] [Abstract][Full Text] [Related]
6. Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus.
Shinozaki S; Tahara T; Lefor AK; Ogura M
J Med Invest; 2020; 67(3.4):280-284. PubMed ID: 33148902
[TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin for nonalcoholic fatty liver disease: A systematic review and meta-analysis.
He K; Li J; Xi W; Ge J; Sun J; Jing Z
Diabetes Res Clin Pract; 2022 Mar; 185():109791. PubMed ID: 35202771
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Chehrehgosha H; Sohrabi MR; Ismail-Beigi F; Malek M; Reza Babaei M; Zamani F; Ajdarkosh H; Khoonsari M; Fallah AE; Khamseh ME
Diabetes Ther; 2021 Mar; 12(3):843-861. PubMed ID: 33586120
[TBL] [Abstract][Full Text] [Related]
9. Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
Taheri H; Malek M; Ismail-Beigi F; Zamani F; Sohrabi M; Reza Babaei M; Khamseh ME
Adv Ther; 2020 Nov; 37(11):4697-4708. PubMed ID: 32975679
[TBL] [Abstract][Full Text] [Related]
10. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
Kuchay MS; Krishan S; Mishra SK; Farooqui KJ; Singh MK; Wasir JS; Bansal B; Kaur P; Jevalikar G; Gill HK; Choudhary NS; Mithal A
Diabetes Care; 2018 Aug; 41(8):1801-1808. PubMed ID: 29895557
[TBL] [Abstract][Full Text] [Related]
11. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis.
Ma YY; Li L; Yu CH; Shen Z; Chen LH; Li YM
World J Gastroenterol; 2013 Oct; 19(40):6911-8. PubMed ID: 24187469
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD.
Hadi A; Mohammadi H; Miraghajani M; Ghaedi E
Crit Rev Food Sci Nutr; 2019; 59(15):2494-2505. PubMed ID: 29584449
[No Abstract] [Full Text] [Related]
13. Functional foods and dietary supplements in the management of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Wang LL; Zhang PH; Yan HH
Front Nutr; 2023; 10():1014010. PubMed ID: 36866059
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic outcome of dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
Hu C; Qu T; Li L; Huang Y; Liu H; Rao C
Afr Health Sci; 2023 Jun; 23(2):416-421. PubMed ID: 38223613
[TBL] [Abstract][Full Text] [Related]
15. The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis: An up-to date systematic review and meta-analysis of randomized controlled trials.
Jalali M; Rahimlou M; Mahmoodi M; Moosavian SP; Symonds ME; Jalali R; Zare M; Imanieh MH; Stasi C
Pharmacol Res; 2020 Sep; 159():104799. PubMed ID: 32278041
[TBL] [Abstract][Full Text] [Related]
16. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway.
Meng Z; Liu X; Li T; Fang T; Cheng Y; Han L; Sun B; Chen L
Int Immunopharmacol; 2021 May; 94():107492. PubMed ID: 33647823
[TBL] [Abstract][Full Text] [Related]
17. The Relationship between Prebiotic Supplementation and Anthropometric and Biochemical Parameters in Patients with NAFLD-A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Stachowska E; Portincasa P; Jamioł-Milc D; Maciejewska-Markiewicz D; Skonieczna-Żydecka K
Nutrients; 2020 Nov; 12(11):. PubMed ID: 33187278
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of HuoXueHuaYu therapy for nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trial.
Cai Y; Liang Q; Chen W; Chen M; Chen R; Zhang Y; Xiao Y; Chen L
BMC Complement Altern Med; 2019 Jul; 19(1):178. PubMed ID: 31324247
[TBL] [Abstract][Full Text] [Related]
19. Does turmeric/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease? A systematic review and meta-analysis of randomized controlled trials.
Goodarzi R; Sabzian K; Shishehbor F; Mansoori A
Phytother Res; 2019 Mar; 33(3):561-570. PubMed ID: 30653773
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of orlistat in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Wang H; Wang L; Cheng Y; Xia Z; Liao Y; Cao J
Biomed Rep; 2018 Jul; 9(1):90-96. PubMed ID: 29930810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
